Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794458

Cover Image

PUBLISHER: Global Industry Analysts, Inc. | PRODUCT CODE: 1794458

Menstrual Drugs

PUBLISHED:
PAGES: 290 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF & Excel (Single User License)
USD 5850
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries)
USD 17550

Add to Cart

Description

Table of Contents

Global Menstrual Drugs Market to Reach US$12.4 Billion by 2030

The global market for Menstrual Drugs estimated at US$8.4 Billion in the year 2024, is expected to reach US$12.4 Billion by 2030, growing at a CAGR of 6.8% over the analysis period 2024-2030. Hormonal Treatment Drugs, one of the segments analyzed in the report, is expected to record a 6.5% CAGR and reach US$4.8 Billion by the end of the analysis period. Growth in the Pain Relief Drugs segment is estimated at 7.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.3 Billion While China is Forecast to Grow at 10.6% CAGR

The Menstrual Drugs market in the U.S. is estimated at US$2.3 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$2.6 Billion by the year 2030 trailing a CAGR of 10.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.5% CAGR.

Global Menstrual Drugs Market - Key Trends & Drivers Summarized

Why Are Menstrual Drugs Gaining Broader Acceptance in Women’s Healthcare?

Menstrual drugs are increasingly being recognized as essential components of comprehensive women’s healthcare, as global awareness about menstrual health rises and stigmas surrounding menstruation continue to erode. These medications are designed to manage a wide array of menstrual-related conditions such as dysmenorrhea (painful periods), menorrhagia (heavy bleeding), premenstrual syndrome (PMS), and premenstrual dysphoric disorder (PMDD). For many women, these drugs significantly improve quality of life by reducing pain, regulating cycles, and stabilizing mood fluctuations. Traditionally, the treatment of menstrual issues was limited to hormonal contraceptives or over-the-counter pain relievers, but the development of more targeted pharmaceutical options has expanded the therapeutic landscape. Non-steroidal anti-inflammatory drugs (NSAIDs), hormonal therapies, antispasmodics, and serotonin reuptake inhibitors are now commonly prescribed, offering diverse solutions tailored to specific symptoms. As women become more proactive about managing their reproductive health, the demand for menstrual drugs is growing across both developed and developing regions. Educational campaigns, social media awareness, and healthcare provider advocacy have further reduced the cultural silence surrounding menstruation. Governments and NGOs are also increasingly including menstrual management as part of public health initiatives, especially in school health programs and women-focused outreach. These collective efforts are creating an environment where menstrual drugs are no longer viewed as optional but are instead recognized as central to women's physical, emotional, and social well-being.

How Are Pharmaceutical Innovations Transforming the Effectiveness and Safety of Menstrual Drugs?

Pharmaceutical advancements are playing a critical role in enhancing both the effectiveness and safety profile of menstrual drugs, leading to better patient outcomes and greater confidence in treatment options. One of the most significant developments is the evolution of hormone-based therapies, which are now being engineered with lower doses and more targeted delivery mechanisms to minimize side effects while maximizing efficacy. Extended-cycle oral contraceptives, hormone-releasing intrauterine devices (IUDs), and transdermal patches are offering long-term solutions for women with chronic menstrual disorders. In parallel, newer generations of NSAIDs with improved gastrointestinal tolerability are being introduced to manage menstrual pain more safely, especially for long-term use. Biotechnology is also contributing to innovation in menstrual health, with research exploring gene expression and hormonal modulation to better understand and treat conditions like endometriosis and PMDD. Additionally, digital therapeutics and app-based platforms are beginning to be paired with pharmacological solutions, helping women track symptoms and optimize treatment timing for maximum benefit. Drug developers are increasingly focusing on personalized medicine approaches, recognizing that menstrual health varies widely based on genetics, lifestyle, and co-existing health conditions. Efforts are also underway to develop non-hormonal therapies for women who are unable or unwilling to use hormonal drugs, further broadening treatment inclusivity. These innovations are not only improving the therapeutic value of menstrual drugs but also reducing the hesitation or fear previously associated with long-term treatment plans, especially among adolescents and first-time users.

How Do Cultural Norms and Regional Healthcare Access Influence the Adoption of Menstrual Drugs?

Cultural beliefs, healthcare infrastructure, and regional awareness levels greatly influence the adoption of menstrual drugs across different parts of the world. In developed countries, where healthcare access is relatively widespread and conversations around women’s health are more normalized, the usage of menstrual drugs is supported by routine gynecological care and broad pharmaceutical availability. In contrast, in many developing and low-income regions, socio-cultural taboos, religious restrictions, and misinformation still hinder women from seeking medical assistance for menstrual disorders. As a result, many women rely on home remedies or endure symptoms in silence, delaying diagnosis and treatment. However, this trend is gradually changing, thanks to the efforts of advocacy groups, international health organizations, and educational campaigns aimed at destigmatizing menstruation and promoting menstrual equity. Mobile clinics, school-based health programs, and telemedicine platforms are improving rural and underserved populations’ access to menstrual drugs and information. Economic factors also play a role, as the affordability of drugs influences whether women can commit to long-term treatment. Governments in some countries are beginning to subsidize or include menstrual drugs in essential medicine lists, which is encouraging broader use and integration into primary healthcare services. Furthermore, the inclusion of menstrual health education in school curricula is equipping young women with the knowledge and confidence to seek medical help early. These shifting social dynamics are steadily reshaping the menstrual drug market, making it more inclusive and responsive to regional diversity and healthcare disparities.

What Are the Main Drivers Accelerating the Growth of the Global Menstrual Drugs Market?

The growth in the menstrual drugs market is driven by several interrelated trends across healthcare policy, pharmaceutical innovation, consumer behavior, and societal change. First, the rising prevalence of menstrual disorders such as PCOS, endometriosis, and severe dysmenorrhea is fueling clinical demand for effective pharmaceutical interventions. Second, increasing healthcare access and insurance coverage in both developed and emerging markets are making menstrual treatments more affordable and widespread. Third, greater societal openness and the destigmatization of menstruation are encouraging more women to seek medical solutions rather than suffer in silence. Fourth, the diversification of treatment options, including the development of non-hormonal and plant-based drugs, is attracting a wider range of users with different needs and preferences. Fifth, the expansion of digital health platforms is facilitating remote consultations and personalized treatment plans, making it easier for women to initiate and manage their care. Sixth, targeted marketing campaigns and awareness initiatives led by women-centric brands and health organizations are educating consumers and improving product visibility. Seventh, increased investment in women’s health by both public agencies and private pharmaceutical companies is accelerating research and development of safer, more effective menstrual therapies. Lastly, the integration of menstrual health into global reproductive health and wellness agendas is cementing its importance in long-term healthcare planning. Collectively, these drivers are contributing to a more mature and resilient menstrual drug market, one that supports a proactive and empowered approach to managing menstrual health around the world.

SCOPE OF STUDY:

The report analyzes the Menstrual Drugs market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs, Other Drug Types); Administration Route (Oral Administration, Injectable Administration, Topical Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • Abbott Laboratories
  • Alembic Pharmaceuticals Ltd.
  • Amneal Pharmaceuticals Inc.
  • Bayer AG
  • Cadila Healthcare (Zydus)
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Endo International plc
  • F. Hoffmann-La Roche Ltd.
  • Gedeon Richter Plc.
  • Glenmark Pharmaceuticals
  • HRA Pharma (a Perrigo company)
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc. (MSD)
  • Novartis AG
  • Pfizer Inc.
  • Sanofi S.A.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Show more
Product Code: MCP37367

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Menstrual Drugs - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Awareness of Menstrual Health Throws the Spotlight on Therapeutic Solutions for Pain and Cycle Regulation
    • Increased Diagnosis of Conditions Like Endometriosis and PCOS Propels Growth in Hormonal and Anti-Inflammatory Drug Use
    • Growing Demand for Non-Opioid Pain Relief Expands the Addressable Market Opportunity for NSAIDs and Natural Alternatives
    • Shift Toward Over-the-Counter and Self-Care Solutions Strengthens the Business Case for Easily Accessible Menstrual Medications
    • Evolving Societal Attitudes Toward Menstrual Wellness Accelerate Demand for Targeted, Symptom-Specific Drugs
    • Product Innovation in Extended-Release and Combination Formulations Drives Adoption Among Younger Demographics
    • Rising Use of Oral Contraceptives for Menstrual Management Spurs Dual-Benefit Drug Utilization
    • Telehealth and DTC Women's Health Platforms Throw the Spotlight on Digital Access to Menstrual Prescriptions
    • Increased Focus on Quality of Life and Workplace Productivity Supports Greater Use of Period Pain Medications
    • Demand for Plant-Based and Hormone-Free Menstrual Relief Products Drives Growth in Complementary Therapies
    • Clinical Interest in Personalized Medicine and Hormone Profiling Expands Potential for Tailored Menstrual Drug Regimens
    • Menstrual Tracking Apps and Digital Health Tools Generate Insights That Spur Demand for Proactive Pharmaceutical Interventions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Menstrual Drugs Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Menstrual Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 4: World 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormonal Treatment Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 7: World 16-Year Perspective for Hormonal Treatment Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Pain Relief Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 10: World 16-Year Perspective for Pain Relief Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for PMS & PMDD Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 13: World 16-Year Perspective for PMS & PMDD Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Menstrual Regulation Drugs by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 16: World 16-Year Perspective for Menstrual Regulation Drugs by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 19: World 16-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Oral Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 22: World 16-Year Perspective for Oral Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Injectable Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 25: World 16-Year Perspective for Injectable Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Topical Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 28: World 16-Year Perspective for Topical Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 34: USA 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • JAPAN
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • CHINA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 49: China 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 52: China 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • EUROPE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Menstrual Drugs by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 55: Europe 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 58: Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • FRANCE
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 64: France 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 67: France 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • GERMANY
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 70: Germany 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 73: Germany 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 76: Italy 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 79: Italy 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED KINGDOM
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 82: UK 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 85: UK 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 88: Spain 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 91: Spain 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 94: Russia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 97: Russia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ASIA-PACIFIC
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Menstrual Drugs by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AUSTRALIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 115: Australia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 118: Australia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • INDIA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 121: India 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 124: India 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 127: South Korea 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 130: South Korea 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • LATIN AMERICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Menstrual Drugs by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 139: Latin America 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 142: Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 145: Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 148: Argentina 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 151: Argentina 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 154: Brazil 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 157: Brazil 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 160: Mexico 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 163: Mexico 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • MIDDLE EAST
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Menstrual Drugs by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 172: Middle East 16-Year Perspective for Menstrual Drugs by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 175: Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 178: Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 181: Iran 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 184: Iran 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 187: Israel 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 190: Israel 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 199: UAE 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 202: UAE 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030
  • AFRICA
    • Menstrual Drugs Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Menstrual Drugs by Drug Type - Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 211: Africa 16-Year Perspective for Menstrual Drugs by Drug Type - Percentage Breakdown of Value Sales for Hormonal Treatment Drugs, Pain Relief Drugs, PMS & PMDD Drugs, Menstrual Regulation Drugs and Other Drug Types for the Years 2014, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Menstrual Drugs by Administration Route - Oral Administration, Injectable Administration and Topical Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
    • TABLE 214: Africa 16-Year Perspective for Menstrual Drugs by Administration Route - Percentage Breakdown of Value Sales for Oral Administration, Injectable Administration and Topical Administration for the Years 2014, 2025 & 2030

IV. COMPETITION

Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!